Nimotuzumab
Nimotuzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target epidermal growth factor receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
129 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | 32 | 11 | 1 | 4 | 46 |
| Nasopharyngeal carcinoma | D000077274 | — | — | — | 12 | 7 | 1 | 1 | 21 |
| Nasopharyngeal neoplasms | D009303 | — | — | — | 9 | 6 | 1 | — | 16 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 7 | 3 | 1 | 1 | 10 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma | D002294 | — | — | 2 | 20 | 5 | — | 3 | 26 |
| Esophageal neoplasms | D004938 | — | C15 | 2 | 12 | 3 | — | — | 16 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 2 | 13 | 4 | — | — | 15 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 1 | 8 | 3 | — | — | 11 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 6 | 1 | — | 3 | 10 |
| Neoplasms | D009369 | — | C80 | 3 | 4 | 2 | — | 1 | 10 |
| Chemoradiotherapy | D059248 | — | — | — | 4 | 2 | — | — | 6 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 4 | 1 | — | — | 5 |
| Adenocarcinoma | D000230 | — | — | — | 4 | 2 | — | — | 5 |
| Colorectal neoplasms | D015179 | — | — | 2 | 4 | 1 | — | — | 5 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 5 | 9 | — | — | 2 | 13 |
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 7 | — | — | 2 | 11 |
| Squamous cell neoplasms | D018307 | — | — | 1 | 4 | — | — | — | 4 |
| Oropharyngeal neoplasms | D009959 | — | — | — | 2 | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | — | — | — | 2 |
| Adenosquamous carcinoma | D018196 | — | — | — | 2 | — | — | — | 2 |
| Drug therapy | D004358 | — | — | — | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | — | 1 | — | — | — | 1 |
| Hypopharyngeal neoplasms | D007012 | — | C13 | — | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adoptive transfer | D019264 | — | — | 1 | — | — | — | — | 1 |
| Antibody-dependent cell cytotoxicity | D000920 | — | — | 1 | — | — | — | — | 1 |
| Cellular immunity | D007111 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nimotuzumab |
| INN | nimotuzumab |
| Description | Nimotuzumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >3GKW:H|Heavy chain of the antibody Nimotuzumab
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAY
MELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVP
>3GKW:L|Light chain of the antibody Nimotuzumab
DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTI
SSLQPEDIATYYCFQYSHVPWTFGQGTKLQITREVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 3GKW |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108359 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 6NS400BXKH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
EGFR
EGFR
Organism
Homo sapiens
Gene name
EGFR
Gene synonyms
ERBB, ERBB1, HER1
NCBI Gene ID
Protein name
epidermal growth factor receptor
Protein synonyms
avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, EGFR vIII, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Uniprot ID
Mouse ortholog
Egfr (13649)
epidermal growth factor receptor (Q01279)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,122 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
51 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use